U.S. markets closed

Gain Therapeutics, Inc. (GANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.2700+0.0100 (+0.31%)
At close: 04:00PM EST
3.3200 +0.05 (+1.53%)
After hours: 07:19PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Shooting Star

Shooting Star

Previous Close3.2600
Bid2.5600 x 800
Ask3.5400 x 1100
Day's Range3.2183 - 3.2899
52 Week Range2.3300 - 6.7000
Avg. Volume28,664
Market Cap38.859M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2340
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GANX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Gain Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 08/31/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • Zacks

    Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

    Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

    Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer and Appointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securities as of September 30, 2022 Provides Strong Financial Foundation and Extends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics,

  • Benzinga

    Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program

    Gain Therapeutics Inc (NASDAQ: GANX) announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson's Disease. The study was conducted using human-induced pluripotent stem cells (iPSC) derived from donor patients with GBA-associated Parkinson's disease, which were then differentiated into dopaminergic neurons. GT-02287 demonstrated statistically significant, positive effects across a range of meas